Pharmacokinetic and Pharmacodynamic Principles of Anti-infective DosingNikolas J. Onufrak, Daniel González, Alan Forrest|Clinical Therapeutics|2016Cited by 170
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophreniaVidya Perera, Andrew J. McLachlan, Annette S. Gross et al.|Expert Opinion on Drug Metabolism & Toxicology|2013Cited by 39
Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal WomenJulie B. Dumond, Angela D. M. Kashuba, Myron S. Cohen et al.|Clinical Pharmacokinetics|2012Cited by 26
Challenges and Solutions for Future Pharmacy Practice in the Era of Precision MedicineOlivia M Dong, Tim Wiltshire, Rachel Howard et al.|American Journal of Pharmaceutical Education|2017Cited by 6
Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16 <sup>INK4a</sup> Expression in Subjects on Combination TherapyJulie B. Dumond, Alan Forrest, Owen Francis et al.|Antiviral Therapy|2015Cited by 5